Cue Biopharma
78 hedge funds and large institutions have $50.5M invested in Cue Biopharma in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
17% more capital invested
Capital invested by funds: $43M → $50.5M (+$7.51M)
4.15% more ownership
Funds ownership: 27.93% → 32.07% (+4.1%)
Holders
78
Holding in Top 10
–
Calls
$586K
Puts
$111K
Top Buyers
| 1 | +$5.12M | |
| 2 | +$1.86M | |
| 3 | +$1.44M | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.01M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$924K |
Top Sellers
| 1 | -$4.11M | |
| 2 | -$609K | |
| 3 | -$536K | |
| 4 |
VC
Voss Capital
Houston,
Texas
|
-$446K |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
-$438K |